| 1 |
Torre R L, Miller K D, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin，2017, 67(1): 7-30.
|
| 2 |
Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA CancerJ Clin, 2015, 65(2): 87-108.
|
| 3 |
Torre L A, Siegel R L, Jemal A. Lung cancer statistics[J]. Adv Exp Med Biol，2016, 893: 1-19.
|
| 4 |
Ai X, Guo X, Wang J, et al. Targeted therapies for advanced non-small cell lung cancer. Oncotarget, 2018, 9(101): 37589-37607.
|
| 5 |
Devarakonda S, Morgensztern D, Govindan R. Molecularly targetedtherapies in locally advanced non-small-cell lung cancer[J]. Clin Lung Cancer，2013, 14(5): 467-472.
|
| 6 |
Moya-Horno I, Viteri S, Karachaliou N, et al. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC) [J]. Ther Adv Med Oncol，2018，10:1758834017745012.
|
| 7 |
曹宝山．刘燕娥．尹文琤，等. 非小细胞肺癌腹膜转移预后因素的单中心回顾性分析[J]. 中国肺癌杂志J, 2019，22(3):143-150.
|
| 8 |
Satoh H, Ishikawa H, Yamashita YT, et al. Peritoneal carcinomatosis in lung cancer patients[J]. Oncol Rep, 2001, 8(6): 1305-1307.
|
| 9 |
Sereno M, Rodriguez-Esteban I, Gomez-Raposo C, et al. Lung cancer and peritoneal carcinomatosis[J]. Oncol Lett, 2013, 6(3): 705-708.
|
| 10 |
Niu F Y, Zhou Q, Yang J J, et al. Distribution and prognosis of uncommon metastases from non-small cell lung cancer[J]. BMC Cancer, 2016, 16: 149.
|
| 11 |
Patil T, Aisner D L, Noonan S A, et al. Malignant pleural diseaseis highly associated with subsequent peritoneal metastasis in patients with stage Ⅳ non-small cell lung cancer independent of oncogene status[J]. Lung Cancer, 2016, 96: 27-32.
|
| 12 |
Su H T, Tsai C M, Perng R P. Peritoneal carcinomatosis in lung cancer[J]. Respirology, 2008, 13(3): 465-467.
|
| 13 |
Diop A D, Fontarensky M, Montoriol PF, et al. CT imaging of peritoneal carcinomatosis and its mimics[J]. Diagn Interv Imaging, 2014，95(9): 861-872.
|
| 14 |
Detterbeck F C, Boffa D J, Tanoue LT. The new lung cancer staging system[J]．Chest 2009, 136(1): 260-271.
|
| 15 |
曾军，周夏飞，杨帆，等．非小细胞肺癌罕见转移分布与预后的相关性分析 [J]. 成都医学院学报，218, 13(6): 723-726.
|
| 16 |
Hsu J F, Lee Y L, Chang H L, et al. Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung[J]. Asia Pac J Clin Oncol, 2019, 15(5):e126-e131.
|
| 17 |
Takagi Y, Sato T, Morio Y, et al. A pleuro-peritoneal communication through the diaphragm affected with lymphangioleiomyomatosis[J]. Intern Med, 2010, 49(5): 439-445.
|
| 18 |
Abbate M I, Cortinovis D L, Tiseo M, et al. Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review[J]. Future Oncol, 2019, 15(9):989-994.
|
| 19 |
Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions[J]. Clin Cancer Res, 1999, 5(11): 3364-3368.
|
| 20 |
Verheul HM, Hoekman K, Jorna AS, et al. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation[J]. Oncologist, 2000, 5 (Suppl 1):S45-S50.
|
| 21 |
Kobayashi H, Wakuda K, Takahashi T. Effectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosis[J]. Respirol Case Rep, 2016, 4(6): e00197.
|